Newsroom

Sorted by: Latest

-

Plural sammelt 1 Mrd. € ein: Kapital für Tech-Pionier:innen, die ein neues Europa gestalten

London, Tallinn und Paris--(BUSINESS WIRE)--Plural, ein von Gründer:innen und erfahrenen operativen Führungskräften geleiteter Frühphasen-Investmentfonds, hat eine Milliarde Euro eingesammelt, um Gründer:innen zu unterstützen, auf die Europa setzt. Plurals Ziel ist es, Europa so stark zu prägen, dass sich dies auf das Bruttoinlandsprodukt auswirkt. Das Unternehmen unterstützt Gründer:innen, die das entwickeln, was eine sich wandelnde Welt im nächsten Jahrzehnt am dringendsten benötigt: Energie,...
-

Plural Raises €1bn to Back the Frontier Founders Building a New Europe

LONDON, TALLINN, Estonia & PARIS--(BUSINESS WIRE)--Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US...
-

ViiV Healthcare’s Tivicay and Dovato receive positive CHMP opinion for young children living with HIV, advancing efforts to close paediatric treatment gaps in the EU

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Tivicay (dolutegravir [DTG]) and Dovato (dolutegravir/lamivudine [DTG/3TC]) to extend their use to eligible younger age groups. Globally around 50% of untreated infants living with HIV die by age two and only 55% of ch...
-

Plural lève €1 milliard pour soutenir les entrepreneurs de la deep tech qui bâtissent une nouvelle Europe

Londres, Tallinn et Paris--(BUSINESS WIRE)--Plural, le fonds d’investissement early-stage dirigé par d’anciens entrepreneurs et dirigeants d’entreprises, annonce avoir levé €1 millions d’euros pour soutenir les entrepreneurs sur lesquels repose l’avenir de l’Europe. L’ambition de Plural est d’avoir un impact sur l’Europe à l’échelle de son PIB. Le fonds soutient les entrepreneurs qui développent les technologies dont le monde aura le plus besoin au cours de la prochaine décennie : énergie, infr...
-

Syntis Bio Reports Late-Breaking SYNTIETY-1 Data at ObesityWeek® 2026 Demonstrating Daily Oral SYNT-101 Mimics Gastric Bypass Hormone Response with Placebo-Like Tolerability

BOSTON--(BUSINESS WIRE)--Syntis Bio, Inc., a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, in two posters, including a late-breaking presentation, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-d...
-

Houlihan Lokey Further Expands Global Oil & Gas Group With Senior Hire in London

LONDON--(BUSINESS WIRE)--Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced the appointment of Fahd Aijaz as a Managing Director in the Oil & Gas Group. Based in London, Mr. Aijaz will lead the firm’s industry coverage of European companies and investors, in collaboration with other senior partners across the global Oil & Gas Group. Mr. Aijaz brings a wealth of expertise in advising leading corporates and private capital investors, having advised on more than 5...
-

LEO Pharma Delivers 11% Revenue Growth at CER and Achieves Strategic Milestones

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma delivers 11% revenue growth at CER and achieves strategic milestones...
-

Nidec Announces Disclosure of the Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2027, Exceeding 45 Days After the Quarter-End

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Company”) hereby announces that the scheduled disclosure date of the financial results for the second quarter of the fiscal year ending March 31, 2027, will exceed 45 days after the quarter-end, as detailed below.We sincerely apologize for any inconvenience and concern caused to our shareholders, investors, and other stakeholders.1. Reason for the Delay in the Disclosure of the Financial ResultsAs announced in th...
-

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools

LUXEMBOURG--(BUSINESS WIRE)--SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000...
-

QurAlis Receives FDA Clearance for IND Application of QRL-201 for the Treatment of ALS, Clearing a Path to Initiation of Pivotal Clinical Trial in the U.S.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QRL-201 for the treatment of amyotrophic lateral sclerosis (ALS). The clearance enables QurAlis to advance the planned pivotal CONQUR clinical trial in the U.S. The company also announced final data from the dose-range finding (DRF) phase of its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-20...